Mike Hennessy Jr.

As industry clinical trial partners seek greater patient diversity and operational efficiencies in drug development, our October issue of Applied Clinical Trials explores some of the related outsourcing methods that are emerging.

Amid the steady introduction of new tech and data advances in study conduct, the September issue of Applied Clinical Trials explores the evolving regulatory landscape governing these efforts and what companies are doing to remain compliant.

No longer "down the road" in their emergence, this issue of Applied Clinical Trials takes a deep look at the impact of decentralized clinical trials to date—and how their future trajectory could shape out.

All the work being done to reduce the carbon footprint in conducting clinical trials circles back to the industry's overarching and ultimate goal: bringing therapies to patients faster.

While recent improvement in clinical trial enrollment levels in cancer may seem modest, there are notable advancements moving the needle in expanding the pool of potential participants, as our May issue explores.

Exploring how the clinical trial enterprise can benefit from new advances and emerging opportunities in digital health technology.

What are the necessary next steps—for all parties involved—in improving diversity in clinical trials?

The evolving role of the CRA is creating shifts in the clinical workforce.

Highlighting a year of conference coverage for ACT.

How important are relationships when it comes to efficiently managing clinical trials?

How does all of industry's newest technology fit together?

MJH Life Sciences, parent company of Applied Clinical Trials, continues to offer many forms of educational content to healthcare professionals.

Increased adoption of decentralized trials and new advancements in technology among reasons for evolving regulatory landscape.

A look at the clinical trials side of oncology.